CJC-1295 & GHRP-6 Blend (10mg) – Research Peptide

CJC-1295 & GHRP-6 Blend (10mg) is an experimental peptide formulation combining two research compounds associated with growth-hormone signalling and pituitary biology. The referenced product contains 5mg CJC-1295 No DAC and 5mg GHRP-6, giving a total peptide content of 10mg.

The blend is supplied as a lyophilised powder and the referenced product listing specifies a stated purity of >99%. CJC-1295 No DAC is investigated as a modified growth-hormone-releasing hormone (GHRH) analogue, while GHRP-6 is a synthetic growth-hormone secretagogue associated with the ghrelin/GHS receptor system.

Research into GHRH and GHRP-6 has identified distinct signalling pathways that can converge on growth-hormone release. Experimental studies have reported amplified GH responses when GHRH and GHRP-6 are investigated together, providing a scientific rationale for studying combinations of these peptide classes. However, findings from individual compounds or other experimental formulations should not be interpreted as proof of efficacy for this specific 10mg blend.

---

What Is the CJC-1295 & GHRP-6 Blend?

The CJC-1295 & GHRP-6 Blend is a two-component research peptide formulation designed for laboratory investigation of growth-hormone-related signalling.

The referenced formulation contains equal quantities of:

• 5mg CJC-1295 No DAC
• 5mg GHRP-6

This produces a total peptide quantity of 10mg and a stated 1:1 ratio by mass. The product is supplied in lyophilised form with a stated purity above 99%.

CJC-1295 No DAC and GHRP-6 are scientifically interesting because they are associated with different receptor systems involved in the regulation of growth-hormone secretion. Research into these pathways provides a useful model for studying how multiple endocrine signals can influence pituitary somatotroph activity.

---

CJC-1295 No DAC – Research Profile

CJC-1295 No DAC is commonly referred to as Modified GRF 1-29 or Mod GRF 1-29. It is a synthetic analogue related to the biologically active region of growth-hormone-releasing hormone.

GHRH is a hypothalamic hormone involved in the regulation of growth-hormone secretion by pituitary somatotroph cells. Consequently, research involving CJC-1295 No DAC focuses on the GHRH receptor pathway, pituitary signalling and mechanisms associated with GH release.

The referenced product specifically identifies its CJC-1295 component as No DAC. This distinction is important because CJC-1295 formulations with and without the Drug Affinity Complex have different pharmacological characteristics and should not automatically be considered interchangeable in research.

---

GHRP-6 – Research Profile

GHRP-6, or growth-hormone-releasing peptide-6, is a synthetic hexapeptide belonging to the growth-hormone secretagogue family.

Research has demonstrated that GHRP-6 acts through a signalling system distinct from the classical GHRH receptor. Growth-hormone secretagogues such as GHRP-6 are associated with the growth-hormone secretagogue receptor (GHS-R), which is closely related to the biological actions of ghrelin.

GHRP-6 has therefore become an important experimental compound for studying growth-hormone secretion, receptor pharmacology and interactions between secretagogue and GHRH pathways.

---

CJC-1295 & GHRP-6 Blend – Product Highlights

• Product name: CJC-1295 & GHRP-6 Blend
• Total quantity: 10mg
• CJC-1295 No DAC: 5mg
• GHRP-6: 5mg
• Blend ratio: 1:1 by stated mass
• Form: Lyophilised powder
• Stated purity: >99%
• General research area: Growth-hormone and pituitary biology
• Research pathways: GHRH and growth-hormone-secretagogue signalling
• Research classification: Experimental peptide blend
• Intended use: Laboratory research

---

CJC-1295 & GHRP-6 Chemical Profile

Property	CJC-1295 No DAC	GHRP-6
Common designation	Mod GRF 1-29	Growth Hormone-Releasing Peptide-6
Quantity	5mg	5mg
Total blend	10mg
Blend ratio	1:1 by mass
Peptide classification	GHRH-related analogue	Growth-hormone secretagogue
Research-associated receptor	GHRH receptor	GHS-R / ghrelin receptor
Physical form	Lyophilised powder
Stated purity	>99%

---

How CJC-1295 and GHRP-6 Differ

Although both peptides are investigated in connection with growth-hormone secretion, they represent different approaches to endocrine signalling.

Feature	CJC-1295 No DAC	GHRP-6
General class	GHRH analogue	Growth-hormone secretagogue
Primary research pathway	GHRH receptor	GHS-R / ghrelin receptor
Peptide structure	Modified GRF-related peptide	Synthetic hexapeptide
Research focus	GHRH-related pituitary signalling	Secretagogue-mediated GH signalling

Research indicates that GHRP-6 and GHRH can act through distinct receptor-linked pathways, and experimental pituitary studies have found that stimulating both systems can amplify GH release compared with stimulation through either pathway alone.

---

Why Combine CJC-1295 and GHRP-6?

The primary research rationale behind combining CJC-1295 No DAC and GHRP-6 is the investigation of complementary growth-hormone signalling pathways.

CJC-1295 No DAC is associated with the GHRH signalling pathway, whereas GHRP-6 is associated with the growth-hormone-secretagogue receptor system. Experimental research has shown that GHRH and GHRP-6 can produce amplified GH responses when used together in certain research models.

This makes the combination relevant to laboratory studies investigating receptor interaction, pituitary signalling and the mechanisms governing GH secretion.

Importantly, a biological rationale for combining two peptides is not the same as demonstrating clinical efficacy. The exact 5mg/5mg commercial blend requires its own controlled experimental characterisation.

---

Growth-Hormone Signalling Research

Growth hormone is regulated by a complex network involving the hypothalamus, pituitary gland and peripheral tissues.

Several important signalling components include:

• GHRH: A hypothalamic hormone involved in stimulating pituitary GH secretion.
• Somatostatin: A major inhibitory regulator of GH release.
• GHS-R: The receptor system associated with ghrelin and synthetic growth-hormone secretagogues.
• Growth hormone: A pituitary hormone involved in numerous physiological processes.
• IGF-1: A downstream growth factor associated with the GH–IGF-1 axis.

Research involving CJC-1295 and GHRP-6 can therefore help investigate how separate upstream signalling mechanisms converge on pituitary growth-hormone secretion.

---

Research Into GHRH and GHRP-6 Interaction

Experimental evidence has long suggested that GHRH and GHRP-6 operate through distinct signalling mechanisms.

Studies using pituitary cells found that GHRH and GHRP-6 could stimulate GH release through separate receptor-linked pathways. When both secretagogues were applied together, their effects on GH release were amplified, supporting the concept of interaction between the two systems.

Additional research has indicated that endogenous GHRH contributes to the full expression of GHRP-6 activity, providing further evidence that the pathways can interact physiologically.

These findings provide useful background for studying CJC-1295 No DAC and GHRP-6 together, although research involving native GHRH should not be treated as direct evidence for the exact CJC-1295 formulation.

---

GHRP-6 and the Ghrelin Receptor

The growth-hormone secretagogue receptor is closely associated with the biological actions of ghrelin, a naturally occurring peptide hormone.

Research has demonstrated that GHRP-6 can act as a peptide agonist of the ghrelin receptor system. Studies comparing GHRP-6 and ghrelin have examined receptor binding, intracellular signalling and downstream responses.

This receptor-level activity is one reason GHRP-6 is frequently used in experimental studies investigating growth-hormone secretagogue pharmacology.

---

CJC-1295 No DAC vs CJC-1295 With DAC

Researchers should distinguish between CJC-1295 preparations with and without the Drug Affinity Complex (DAC).

Feature	CJC-1295 No DAC / Mod GRF 1-29	CJC-1295 With DAC
DAC	Absent	Present
General classification	Modified GHRH-related peptide	Longer-acting CJC-1295 preparation
Research consideration	Should be characterised independently	Different pharmacokinetic profile

The product referenced here specifically lists CJC-1295 No DAC. Research involving DAC-containing preparations should therefore be evaluated separately when comparing experimental results.

---

Potential Research Applications

The CJC-1295 & GHRP-6 Blend may be of interest for controlled laboratory investigations involving:

• Pituitary biology: Research into somatotroph-cell responses.
• Growth-hormone secretion: Investigation of mechanisms regulating GH release.
• GHRH receptor signalling: Study of modified GHRH-related peptides.
• GHS receptor research: Investigation of GHRP-6 and ghrelin-receptor signalling.
• Peptide pharmacology: Comparison of different growth-hormone secretagogues.
• Receptor interaction studies: Investigation of complementary signalling pathways.
• Endocrine research: Study of the wider GH regulatory axis.
• GH–IGF-1 research: Investigation of relationships between GH signalling and downstream growth-factor pathways.
• Analytical research: Peptide identity, purity and stability characterisation.

---

Understanding the 10mg Formulation

The 10mg designation refers to the total amount of peptide material in the referenced product.

• 5mg CJC-1295 No DAC
• 5mg GHRP-6

The two peptides are therefore supplied in a stated 1:1 ratio by mass. The 10mg specification is a product quantity and should not be interpreted as a dosage recommendation or clinical treatment quantity.

---

Lyophilised Peptide Format

The product is supplied as a lyophilised powder. Lyophilisation, commonly called freeze-drying, is frequently used for peptide research materials.

The dry format is suitable for laboratory handling and analytical characterisation when managed according to appropriate research protocols. Researchers should consult the applicable product documentation and institutional procedures when handling experimental peptide materials.

---

Research Quality and Analytical Characterisation

Accurate peptide research requires reliable information about the identity and purity of experimental materials.

Common analytical approaches used in peptide research include:

• HPLC: Used to evaluate chromatographic purity.
• Mass spectrometry: Used to support molecular identity and molecular-mass determination.
• Certificate of Analysis: Provides batch-specific analytical information where supplied.
• Lot tracking: Supports experimental reproducibility and traceability.

The referenced product listing specifies a stated purity of >99%.

---

Research Evidence and Scientific Context

GHRP-6 has been studied extensively as a synthetic growth-hormone secretagogue. Early research identified a distinct receptor system through which synthetic secretagogues stimulate GH secretion, separate from the classical GHRH receptor.

Subsequent studies established a close relationship between the growth-hormone secretagogue system and ghrelin signalling. GHRP-6 has been examined in receptor-binding and signal-transduction studies as an agonist of the ghrelin receptor system.

Research involving GHRH and GHRP-6 has also demonstrated that the two pathways can interact. Experimental pituitary-cell work has shown that simultaneous stimulation can amplify GH release, providing a mechanistic basis for investigating combinations of GHRH-related compounds and GHRP-6.

---

Research Limitations

Although the individual components have been investigated in scientific studies, several limitations should be considered when evaluating this product.

• Exact blend evidence: Research involving CJC-1295 or GHRP-6 individually does not establish the properties of this precise 5mg/5mg formulation.
• Different CJC-1295 preparations: No-DAC and DAC-containing formulations have different characteristics and should be assessed separately.
• Experimental evidence: Animal, cellular and mechanistic research cannot automatically be translated into human therapeutic outcomes.
• Clinical efficacy: Research activity involving GH signalling does not establish efficacy for weight management, athletic performance, recovery or other consumer uses.
• Safety: The long-term safety profile of unapproved peptide blends remains insufficiently characterised.
• Complex endocrine effects: Growth-hormone secretagogues can interact with multiple hormonal and metabolic pathways.

---

Frequently Asked Questions About CJC-1295 & GHRP-6 Blend (10mg)

What is CJC-1295 & GHRP-6 Blend (10mg)?

It is an experimental peptide blend containing 5mg CJC-1295 No DAC and 5mg GHRP-6, providing a total of 10mg of peptide material.

What is the ratio of CJC-1295 to GHRP-6?

The referenced formulation contains a stated 1:1 ratio by mass, with 5mg of each peptide.

What is CJC-1295 No DAC?

CJC-1295 No DAC is commonly referred to as Modified GRF 1-29 and is studied as a GHRH-related peptide associated with the GHRH receptor pathway.

What is GHRP-6?

GHRP-6 is a synthetic hexapeptide classified as a growth-hormone secretagogue. Research has associated it with the growth-hormone secretagogue/ghrelin receptor system.

Why are CJC-1295 and GHRP-6 combined?

The combination allows researchers to investigate two complementary signalling pathways involved in growth-hormone regulation. Experimental research has reported amplified GH responses when GHRH and GHRP-6 pathways are stimulated together.

What does the 10mg specification mean?

It represents the total peptide quantity in the formulation: 5mg CJC-1295 No DAC plus 5mg GHRP-6.

Is CJC-1295 No DAC the same as CJC-1295 with DAC?

No. The No-DAC and DAC-containing forms have different characteristics. The product referenced here specifically contains CJC-1295 No DAC.

What form is the product supplied in?

The referenced product is supplied as a lyophilised powder.

What is the stated purity?

The referenced product listing specifies a stated purity of >99%.

Is the 10mg quantity a human dosage?

No. The 10mg figure describes the amount of research material supplied and is not a recommendation for human administration.

Does research prove that this exact blend has synergistic effects?

No. Studies of GHRH and GHRP-6 provide a scientific rationale for investigating complementary signalling, but evidence from other experimental models does not establish the clinical or biological effects of this exact commercial blend.

Is this product an approved medicine?

No. It is presented as an experimental research peptide blend and should not be represented as an approved medicinal product or established treatment.

---

CJC-1295 & GHRP-6 Blend (10mg) Research Summary

CJC-1295 & GHRP-6 Blend (10mg) is a two-peptide experimental formulation containing equal quantities of CJC-1295 No DAC and GHRP-6. The referenced product contains 5mg of each peptide, for a total of 10mg, in a lyophilised powder format with a stated purity above 99%.

CJC-1295 No DAC is investigated in relation to GHRH receptor signalling, while GHRP-6 is a growth-hormone secretagogue associated with the GHS/ghrelin receptor system. Research indicates that these signalling pathways are distinct but can interact in the regulation of pituitary GH secretion.

This makes the combination scientifically relevant for research into growth-hormone secretion, pituitary biology, receptor signalling and endocrine pathway interactions. Nevertheless, evidence concerning individual peptides or related experimental combinations should not be presented as direct proof of the effects of this specific 10mg formulation.

---

Research-Use Disclaimer

CJC-1295 & GHRP-6 Blend (10mg) is intended for laboratory and research use only. It is not a medicine, dietary supplement, food product or approved therapeutic treatment.

The information in this product description is provided for scientific and educational purposes. It summarises research associated with the individual peptide components and their signalling pathways and should not be interpreted as evidence that this blend can diagnose, treat, cure or prevent any disease or medical condition.

Research findings involving individual peptides, native GHRH, other GHRH analogues, different CJC-1295 preparations or separate GHRP-6 formulations should not automatically be attributed to this exact product.

This description does not provide instructions for human administration, dosing, injection, reconstitution for human use or self-experimentation. Researchers should consult relevant scientific literature, batch-specific analytical documentation, institutional procedures and applicable laws and regulations when working with experimental peptide materials.